Israel Biotech Fund
Ken Somberg is a Venture Advisor at Israel Biotech Fund. Ken is also the Chief Medical Officer at TrialSpark. Dr. Somberg is a pharmaceutical executive with senior leadership experience in global pharma and contract research organizations.
He is the former CMO of Nevakar and Covance with significant prior experience at Novartis Pharmaceuticals as a global therapeutic area head in both Clinical Research (Transplantation and Immunology) and Regulatory Affairs (infectious Diseases, Transplantation, and Immunology).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Israel Biotech Fund
Israel Biotech Fund seeks high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Their key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide their portfolio companies with hands-on guidance and support.